STOCK TITAN

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tempest Therapeutics, Inc. reported that Corporate Controller Justin Trojanowski received a grant of employee stock options for 22,000 shares of common stock. The options have an exercise price of $1.64 per share and expire on March 30, 2036.

According to the vesting terms, 25% of the options will vest on March 31, 2027, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, his reported holdings in these options total 22,000 derivative securities, all held directly.

Positive

  • None.

Negative

  • None.
Insider Trojanowski Justin
Role Corporate Controller
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 22,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 22,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Options granted 22,000 options Employee stock option grant to Corporate Controller
Exercise price $1.64 per share Strike price for the 22,000 options
Expiration date March 30, 2036 Option term end date for the grant
Initial vesting 25% on March 31, 2027 Cliff vest of one-quarter of granted options
Remaining vesting schedule 36 monthly installments Remaining 75% vests monthly after March 31, 2027
Post-grant derivative holdings 22,000 derivative securities Total options held directly after the grant
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
vesting financial
"This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: "1.6400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"total_shares_following_transaction: "22000.0000" for derivative security"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Trojanowski Justin

(Last)(First)(Middle)
C/O TEMPEST THERAPEUTICS, INC.
2000 SIERRA POINT PARKWAY, SUITE 400

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Corporate Controller
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$1.6403/31/2026A22,000 (1)03/30/2036Common Stock22,000$022,000D
Explanation of Responses:
1. This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.
/s/ Nicholas Maestas, Attorney-in-Fact04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tempest Therapeutics (TPST) disclose about Justin Trojanowski in this Form 4?

Tempest Therapeutics disclosed that Corporate Controller Justin Trojanowski received a grant of employee stock options for 22,000 shares of common stock, with an exercise price of $1.64 per share and an expiration date of March 30, 2036.

How many Tempest Therapeutics (TPST) options were granted to Justin Trojanowski?

Justin Trojanowski was granted employee stock options covering 22,000 shares of Tempest Therapeutics common stock. These options represent his total reported derivative holdings following the transaction, as shown in this Form 4 filing for the award.

What is the exercise price and expiration date of Justin Trojanowski’s TPST options?

The granted employee stock options have an exercise price of $1.64 per share and expire on March 30, 2036. This means he can buy Tempest Therapeutics common stock at $1.64 per share any time before the expiration date, once the options vest.

How do the Tempest Therapeutics (TPST) options granted to Justin Trojanowski vest?

The options vest over time: 25% of the 22,000 shares vest on March 31, 2027, and the remaining 75% vest in 36 equal monthly installments afterward, subject to Justin Trojanowski’s continued service with Tempest Therapeutics.

Is Justin Trojanowski’s Form 4 transaction a purchase or a compensation grant of TPST options?

The Form 4 shows a compensation-related grant, not an open-market purchase. The transaction uses code “A” for a grant or award acquisition of employee stock options, giving rights to buy 22,000 TPST shares at a fixed $1.64 exercise price.